BRM412
Neovascular eye diseases occur when abnormal blood vessels form inside the eye. These vessels are fragile and prone to leakage or bleeding, which can damage the retinal photoreceptors and lead to vision loss or even blindness. Common conditions include wet age-related macular degeneration, choroidal neovascularization associated with high myopia, and diabetic retinopathy.In these conditions, the new blood vessels are often unhealthy, penetrating the retina and causing bleeding or swelling. Common symptoms include blurred vision, distorted images, dark spots or flashes in the visual field, and rapid deterioration of central vision. The primary treatment is intravitreal injection of anti-VEGF drugs, which inhibit abnormal blood vessel growth and reduce leakage. Photodynamic therapy and laser photocoagulation are also used depending on the case. Preventive measures include regular eye examinations, quitting smoking, maintaining a balanced diet with antioxidants, and controlling the progression of myopia to reduce the risk of abnormal blood vessel formation and vision damage.
BRM412 is an ophthalmic drug developed using innovative ophthalmic formulation technology incorporating a specialized drug delivery carrier, which is intended to overcome the current limitation of relying primarily on intravitreal injections for the treatment of wet age-related macular degeneration (Wet AMD). By effectively delivering the poorly soluble anti-angiogenic tyrosine kinase inhibitor (TKI), axitinib, to retina and choroid tissue through topical eye drop administration, BRM412 enables a non-invasive treatment approach for patients. Compared with intravitreal injections, BRM412 offers a non-invasive treatment option with better medication compliance that avoids the pain, infection risk, and side effects of injections, such as retinal detachment.
In earlier clinical trials evaluating axitinib for the treatment of Wet AMD, the majority of patients demonstrated potential efficacy in inhibiting neovascularization, with disease control or stabilization observed in some patients who remained free from further intraocular anti-Vascular Endothelial Growth Factor (anti-VEGF) injections for up to nine months. Based on the mechanism of action of axitinib and the results of early clinical trials, BRM412 has continued to undergo formulation development, with the current optimized formulation focused on improving long-term safety, tolerability, and patient comfort. As a non-invasive drop-based therapy, BRM412 not only has the potential to replace current intravitreal injection therapies, but also offers the potential to improve treatment compliance and expand the applicable patient population.
